# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Harriet Tubman (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI005-SYN
- Date: 2026-08-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carmen Ruiz-Delgado, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-month sleepiness and headache review. **S**

## History of present illness

Mrs. Tubman returns three months after starting modafinil and increasing candesartan to 16 mg. She takes modafinil each morning and two scheduled 15-minute naps, and unplanned sleep episodes are now rare, only while seated. Her headache diary shows 21 headache days in the past three months, against 54 before treatment. She uses acetaminophen about once a week and has taken no ibuprofen. She has had no palpitations, insomnia, or loss of appetite on modafinil and no dizziness on candesartan. She is back to running her household and her church work. **S**

| Element | Detail |
|---|---|
| Sleep episodes | Rare and only while seated, with two planned naps a day |
| Headache diary | 21 headache days in three months, down from 54 |
| Acute medicine | Acetaminophen about once a week; no ibuprofen |
| Medication tolerance | No palpitations, insomnia, or appetite loss on modafinil; no dizziness on candesartan |
| Function | Running her household and church work again |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Headaches about seven days a month; rare sleep episodes |
| Cardiovascular | Negative | No palpitations, chest pain, or light-headedness |
| Gastrointestinal | Negative | Appetite normal; no nausea |
| Psychiatric | Negative | Mood good; no anxiety or insomnia; PHQ-9 score 2 |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week **S**
- Candesartan 16 mg oral tablet, one tablet by mouth daily **S**
- Modafinil 100 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/74 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 51.5 kg; BMI 22.3 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 0.88 mg/dL; eGFR: 68 mL/min/1.73 m²; Glucose: 93 mg/dL; PROMIS sleep-related impairment T-score: 55; Headache days in the past 3 months: 21; PHQ-9: 2. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.84 mg/dL at baseline, 0.88 mg/dL at this visit **S**
- eGFR: 72 mL/min/1.73 m² at baseline, 68 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 93 mg/dL at this visit **S**
- PROMIS sleep-related impairment T-score: 68 at baseline, 55 at this visit **S**
- Headache days in the past 3 months: 54 at baseline, 21 at this visit **S**
- PHQ-9: 3 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and well; no spell during the visit |
| Cardiovascular | Regular rhythm; no edema |
| Neurological | Nonfocal; gait normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Narcolepsy without cataplexy due to a medical condition, provisional, improved** (G47.429). PROMIS sleep-related impairment T-score down from 68 to 55, meeting the goal of below 60, with rare unplanned episodes. Blood pressure 124/74 mmHg and pulse 76 on modafinil. **S**
   - Continue modafinil 100 mg each morning and two scheduled naps.
2. **Chronic post-traumatic headache, responding to prevention** (G44.329). Headache days down from 54 to 21 in three months, more than the 50 percent reduction targeted. Potassium 4.5 and creatinine 0.88 (eGFR 68) on candesartan 16 mg. **S**
   - Continue candesartan 16 mg; consider tapering after 6 to 12 months of good control.
   - Continue the headache diary.
3. **Medication-overuse headache, resolved** (G44.40). No NSAIDs since the first visit and acute medicine about once a week. **S**
   - Keep acute medicine to no more than 2 days a week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PROMIS sleep-related impairment | At baseline and after treatment | Completed today | T-score 55, down 13 points from baseline |
| Medication safety | Modafinil: blood pressure and heart rate | Before starting and at follow-up | Completed today | 124/74 mmHg and pulse 76, against 132/80 and 72 before starting |
| Survey | Headache days per three months | 2 to 3 months after starting prevention | Completed today | 21, down from 54 |
| Laboratory | Basic metabolic panel (potassium and creatinine) on candesartan | Before starting and a few weeks after; then periodically | Completed today | Potassium 4.5, creatinine 0.88, eGFR 68, sodium and glucose normal |
| Laboratory | Potassium and creatinine after the candesartan dose increase | A few weeks after a dose increase | Deferred | Not drawn after the dose was doubled three months ago, a gap in usual practice for angiotensin receptor blockers. Today's potassium and creatinine are normal, so no harm resulted. Future dose changes will carry a check in two to four weeks |
| Examination | Blood pressure, heart rate, and weight | Every visit | Completed today | 124/74 mmHg, pulse 76, weight 51.5 kg |
| Self-management | Headache diary (headache days and acute-medicine days) | Daily | Completed today | Reviewed; about seven headache days a month |
| Medication safety | Acute headache medicine on no more than 2 days a week | Every visit | Completed today | Acetaminophen about once a week; no NSAIDs |
| Survey | Depression screen (PHQ-9) | At baseline and at follow-up | Completed today | Score 2 |
| Self-management | Safety advice for sudden sleep episodes | Every visit | Completed today | Reviewed; no episodes while standing, walking, or cooking since starting modafinil |

## Goal progress

- Stop daily over-the-counter analgesics and limit acute headache medicine to no more than 2 days a week. Outcome by 2026-05-18: No ibuprofen since the first visit; acetaminophen about once a week. **S**
- Cut headache days by at least half by the three-month review. Outcome by 2026-08-17: Headache days fell from 54 to 21 in three months. **S**
- Reduce daytime sleep attacks and lower the PROMIS sleep-related impairment T-score below 60. Outcome by 2026-08-17: T-score fell from 68 to 55; one or two planned naps a day and rare unplanned episodes. **S**
- Establish whether the spells are epileptic before considering antiseizure medicine. Outcome by 2026-05-18: Typical spells captured on ambulatory EEG were sleep onset; no antiseizure medicine needed. **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015), American Academy of Neurology and American Epilepsy Society
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021), American Academy of Sleep Medicine
- The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018), Headache Classification Committee of the International Headache Society
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021), American Headache Society

## Follow-up

- Annual wellness visit in the fall. Continue the headache diary and scheduled naps. **S**
- Next scheduled visit 2026-10-13: subsequent annual wellness visit. **S**
